Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avidity Biosciences Inc (NASDAQ: RNA) closed the day trading at $46.43 down -3.55% from the previous closing price of $48.14. In other words, the price has decreased by -$3.55 from its previous closing price. On the day, 0.84 million shares were traded. RNA stock price reached its highest trading level at $48.8012 during the session, while it also had its lowest trading level at $45.73.
Ratios:
For a better understanding of RNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.47 and its Current Ratio is at 12.47. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on May 03, 2024, initiated with a Buy rating and assigned the stock a target price of $40.
On March 14, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $60.
Evercore ISI Upgraded its In-line to Outperform on May 22, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 19 ’24 when LEVIN ARTHUR A sold 5,000 shares for $45.01 per share. The transaction valued at 225,069 led to the insider holds 14,830 shares of the business.
Boyce Sarah sold 28,000 shares of RNA for $1,118,082 on Jul 09 ’24. The President and CEO now owns 205,043 shares after completing the transaction at $39.93 per share. On Jun 20 ’24, another insider, LEVIN ARTHUR A, who serves as the Director of the company, sold 5,000 shares for $37.59 each. As a result, the insider received 187,950 and left with 14,830 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 5003714560 and an Enterprise Value of 3533688320. For the stock, the TTM Price-to-Sale (P/S) ratio is 408.52 while its Price-to-Book (P/B) ratio in mrq is 5.34. Its current Enterprise Value per Revenue stands at 325.086 whereas that against EBITDA is -13.976.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $48.29, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 27.17%, while the 200-Day Moving Average is calculated to be 133.77%.
Shares Statistics:
Over the past 3-months, RNA traded about 1.55M shares per day on average, while over the past 10 days, RNA traded about 1172660 shares per day. A total of 95.64M shares are outstanding, with a floating share count of 86.51M. Insiders hold about 9.54% of the company’s shares, while institutions hold 91.89% stake in the company. Shares short for RNA as of 1721001600 were 12906004 with a Short Ratio of 8.31, compared to 1718323200 on 11266033. Therefore, it implies a Short% of Shares Outstanding of 12906004 and a Short% of Float of 15.15.
